ENCORE: Amikacin Called Safe, Effective for MAC Lung Disease
The phase 3b ENCORE study has shown that Amikacin liposome inhalation suspension (ALIS) is effective for treating treatment-naive patients with Mycobacterium avium complex (MAC) lung disease. The study demonstrated significant improvements in patient-reported symptoms and culture conversion rates when ALIS was used in combination with azithromycin and ethambutol. These findings suggest that ALIS may provide a valuable treatment option for patients with this challenging condition.
- ▪ALIS is FDA approved for treatment-refractory MAC lung disease and shows promise for treatment-naive patients.
- ▪The study involved 425 participants across 22 countries and demonstrated significant improvements in respiratory symptoms and culture conversion rates.
- ▪Patients receiving ALIS showed a statistically significant improvement in quality of life measures compared to the comparator group.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/encore-amikacin-liposome-inhalation-suspension-looks-2026a1000gc8?src=rss |
| Publication time | Wed, 20 May 2026 08:22:47 EDT |
| Retrieval time | 2026-05-20T12:35:02.447Z |
| Last seen | 2026-05-20T12:35:02.447Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 1q_4WZ7nfjrE |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
ORLANDO, Fla. — Amikacin liposome inhalation suspension (ALIS) is already FDA approved to treat people with treatment-refractory Mycobacterium avium complex (MAC) lung disease, and newly announced results of the phase 3b ENCORE study suggest ALIS also holds promise in treatment- naive patients when administered as part of a combination regimen.Investigators compared patient-reported symptoms and culture conversion rates with ALIS vs an empty liposome comparator, each in combination with azithromycin and ethambutol during a 12-month study, and again 1 month and 3 months after stopping treatment.“The take home message would be using ALIS in treatment- naive patients or upfront therapy looks to be effective in two important measures: how the patient feels and microbiologically, with a very…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
